STAA PE Ratio & Valuation,Is STAA Overvalued

STAA Relative Valuation

STAA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, STAA is overvalued; if below, it's undervalued.

Historical Valuation

STAAR Surgical Co (STAA) is now in the Fair zone, suggesting that its current forward PE ratio of 46.83 is considered Fairly compared with the five-year average of 70.38. The fair price of STAAR Surgical Co (STAA) is between 17.61 to 62.85 according to relative valuation methord.

Relative Value

Fair Zone

17.61-62.85

Current Price：22.50

Fair

46.83

27.50

EV/EBITDA

STAAR Surgical Co. (STAA) has a current EV/EBITDA of 27.50. The 5-year average EV/EBITDA is 49.52. The thresholds are as follows: Strongly Undervalued below -61.39, Undervalued between -61.39 and -5.94, Fairly Valued between 104.98 and -5.94, Overvalued between 104.98 and 160.43, and Strongly Overvalued above 160.43. The current Forward EV/EBITDA of 27.50 falls within the Historic Trend Line -Fairly Valued range.

-1976.31

EV/EBIT

STAAR Surgical Co. (STAA) has a current EV/EBIT of -1976.31. The 5-year average EV/EBIT is 13.94. The thresholds are as follows: Strongly Undervalued below -901.82, Undervalued between -901.82 and -443.94, Fairly Valued between 471.81 and -443.94, Overvalued between 471.81 and 929.69, and Strongly Overvalued above 929.69. The current Forward EV/EBIT of -1976.31 falls within the Strongly Undervalued range.

3.74

STAAR Surgical Co. (STAA) has a current PS of 3.74. The 5-year average PS is 9.96. The thresholds are as follows: Strongly Undervalued below -4.74, Undervalued between -4.74 and 2.61, Fairly Valued between 17.31 and 2.61, Overvalued between 17.31 and 24.66, and Strongly Overvalued above 24.66. The current Forward PS of 3.74 falls within the Historic Trend Line -Fairly Valued range.

106.72

P/OCF

STAAR Surgical Co. (STAA) has a current P/OCF of 106.72. The 5-year average P/OCF is 94.17. The thresholds are as follows: Strongly Undervalued below -177.78, Undervalued between -177.78 and -41.81, Fairly Valued between 230.14 and -41.81, Overvalued between 230.14 and 366.12, and Strongly Overvalued above 366.12. The current Forward P/OCF of 106.72 falls within the Historic Trend Line -Fairly Valued range.

1739.13

P/FCF

STAAR Surgical Co. (STAA) has a current P/FCF of 1739.13. The 5-year average P/FCF is 120.11. The thresholds are as follows: Strongly Undervalued below -909.18, Undervalued between -909.18 and -394.53, Fairly Valued between 634.76 and -394.53, Overvalued between 634.76 and 1149.40, and Strongly Overvalued above 1149.40. The current Forward P/FCF of 1739.13 falls within the Strongly Overvalued range.

STAAR Surgical Co (STAA) has a current Price-to-Book (P/B) ratio of 3.29. Compared to its 3-year average P/B ratio of 4.85 , the current P/B ratio is approximately -32.17% higher. Relative to its 5-year average P/B ratio of 10.40, the current P/B ratio is about -68.34% higher. STAAR Surgical Co (STAA) has a Forward Free Cash Flow (FCF) yield of approximately -3.37%. Compared to its 3-year average FCF yield of -0.58%, the current FCF yield is approximately 482.95% lower. Relative to its 5-year average FCF yield of -0.10% , the current FCF yield is about 3397.49% lower.

3.29

P/B

Median3y

4.85

Median5y

10.40

-3.37

FCF Yield

Median3y

-0.58

Median5y

-0.10

Competitors Valuation Multiple

The average P/S ratio for STAA's competitors is 6.36, providing a benchmark for relative valuation. STAAR Surgical Co Corp (STAA) exhibits a P/S ratio of 3.74, which is -41.17% above the industry average. Given its robust revenue growth of 6.93%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of STAA decreased by 8.27% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 88.59M to 94.73M.

The secondary factor is the P/E Change, contributed 1.57%to the performance.

Overall, the performance of STAA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

6.93%

88.59M → 94.73M

Revenue Growth

-16.77%

11.27 → 9.38

Margin Expansion

1.57%

-11.92 → -12.10

P/E Change

-8.27%

24.19 → 22.19

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is STAAR Surgical Co (STAA) currently overvalued or undervalued?

What is STAAR Surgical Co (STAA) fair value?

STAA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of STAAR Surgical Co (STAA) is between 17.61 to 62.85 according to relative valuation methord.

How does STAA's valuation metrics compare to the industry average?

What is the current P/B ratio for STAAR Surgical Co (STAA) as of Jan 09 2026?

As of Jan 09 2026, STAAR Surgical Co (STAA) has a P/B ratio of 3.29. This indicates that the market values STAA at 3.29 times its book value.

What is the current FCF Yield for STAAR Surgical Co (STAA) as of Jan 09 2026?

As of Jan 09 2026, STAAR Surgical Co (STAA) has a FCF Yield of -3.37%. This means that for every dollar of STAAR Surgical Co’s market capitalization, the company generates -3.37 cents in free cash flow.

What is the current Forward P/E ratio for STAAR Surgical Co (STAA) as of Jan 09 2026?

As of Jan 09 2026, STAAR Surgical Co (STAA) has a Forward P/E ratio of 46.83. This means the market is willing to pay $46.83 for every dollar of STAAR Surgical Co’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for STAAR Surgical Co (STAA) as of Jan 09 2026?

As of Jan 09 2026, STAAR Surgical Co (STAA) has a Forward P/S ratio of 3.74. This means the market is valuing STAA at $3.74 for every dollar of expected revenue over the next 12 months.

STAA Valuation